Study Title

A Phase I Study of Pretargeted PET Imaging Using 64Cu-Tz-SarAr and a Trans-Cyclooctene-Modified Humanized 5B1 Immunoconjugate (hu5B1-TCO) in Patients With CA19-9-Positive Pancreatic Cancer

Study Details

Description:

The purpose of this study is to find the highest safe dose of hu5B1-TCO and the best dosing schedule of hu5B1-TCO and 64Cu-Tz-SarAr for finding cancer cells that are CA19-9 positive. This study will also help to find out how much radiation the body is exposed to when 64Cu-Tz-SarAr is used, and provide information on the way the body absorbs, distributes, and gets rid of 64Cu-Tz-SarAr.

Sponsor:

Memorial Sloan Kettering Cancer Center

Contacts:

Neeta Pandit-Taskar, MD (Principal Investigator)

pandit-n@mskcc.org

2126393046

Eileen O'Reilly, MD

oreillye@mskcc.org

6468884182

Government Study Link:

NCT05737615 - Click here to see study on

ClinicalTrials.gov

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468